KR102367723B1 - 브라디키닌 b1 수용체 리간드에 대한 항체 - Google Patents

브라디키닌 b1 수용체 리간드에 대한 항체 Download PDF

Info

Publication number
KR102367723B1
KR102367723B1 KR1020207028912A KR20207028912A KR102367723B1 KR 102367723 B1 KR102367723 B1 KR 102367723B1 KR 1020207028912 A KR1020207028912 A KR 1020207028912A KR 20207028912 A KR20207028912 A KR 20207028912A KR 102367723 B1 KR102367723 B1 KR 102367723B1
Authority
KR
South Korea
Prior art keywords
seq
kallidine
antibody
des
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207028912A
Other languages
English (en)
Korean (ko)
Other versions
KR20200121370A (ko
Inventor
한 리
도로씨아 코미노스
지에 장
알라 프리츠커
매튜 데이비슨
니콜라 보랭
고빈단 서브라마니안
신 첸
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49261064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102367723(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 사노피 filed Critical 사노피
Priority to KR1020227005891A priority Critical patent/KR20220031728A/ko
Publication of KR20200121370A publication Critical patent/KR20200121370A/ko
Application granted granted Critical
Publication of KR102367723B1 publication Critical patent/KR102367723B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207028912A 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체 Active KR102367723B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227005891A KR20220031728A (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261616845P 2012-03-28 2012-03-28
US61/616,845 2012-03-28
FR1350953 2013-02-04
FR1350953 2013-02-04
PCT/US2013/031836 WO2013148296A1 (en) 2012-03-28 2013-03-15 Antibodies to bradykinin b1 receptor ligands
KR1020197030406A KR102166083B1 (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030406A Division KR102166083B1 (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227005891A Division KR20220031728A (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체

Publications (2)

Publication Number Publication Date
KR20200121370A KR20200121370A (ko) 2020-10-23
KR102367723B1 true KR102367723B1 (ko) 2022-02-28

Family

ID=49261064

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020207028912A Active KR102367723B1 (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체
KR1020147029192A Active KR102035882B1 (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체
KR1020227005891A Ceased KR20220031728A (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체
KR1020197030406A Active KR102166083B1 (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020147029192A Active KR102035882B1 (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체
KR1020227005891A Ceased KR20220031728A (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체
KR1020197030406A Active KR102166083B1 (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체

Country Status (38)

Country Link
US (5) US9376494B2 (https=)
EP (2) EP3246339B1 (https=)
JP (5) JP6779012B2 (https=)
KR (4) KR102367723B1 (https=)
CN (3) CN104334578B (https=)
AR (1) AR090352A1 (https=)
AU (2) AU2013240242B2 (https=)
BR (1) BR112014024282A2 (https=)
CA (1) CA2868353C (https=)
CL (2) CL2014002590A1 (https=)
CO (1) CO7111293A2 (https=)
CR (1) CR20140440A (https=)
CY (1) CY1121466T1 (https=)
DK (2) DK2831113T3 (https=)
DO (1) DOP2014000199A (https=)
EA (1) EA201491784A1 (https=)
ES (1) ES2673869T3 (https=)
GT (1) GT201400192A (https=)
HR (1) HRP20180928T1 (https=)
HU (1) HUE037720T2 (https=)
IL (1) IL234830B (https=)
LT (1) LT2831113T (https=)
MA (1) MA37407B1 (https=)
MX (2) MX361874B (https=)
MY (2) MY184037A (https=)
NZ (1) NZ631543A (https=)
PE (1) PE20142170A1 (https=)
PH (1) PH12014501970A1 (https=)
PL (1) PL2831113T3 (https=)
PT (1) PT2831113T (https=)
RS (1) RS57413B1 (https=)
SG (2) SG11201405162YA (https=)
SI (1) SI2831113T1 (https=)
TR (1) TR201808486T4 (https=)
TW (1) TWI605060B (https=)
UA (1) UA117097C2 (https=)
UY (1) UY34682A (https=)
WO (1) WO2013148296A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037720T2 (hu) 2012-03-28 2018-09-28 Sanofi Sa Bradikinin B1 receptor ligandumok elleni antitestek
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
CN105504049B (zh) * 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用
KR102874711B1 (ko) 2015-12-15 2025-10-23 다케다 파머수티컬 컴패니 리미티드 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
MX2018013386A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN118894936A (zh) * 2017-05-08 2024-11-05 阿迪马布有限责任公司 抗cd3结合结构域和包含它们的抗体以及它们的产生及使用方法
TW201945026A (zh) * 2018-01-29 2019-12-01 美商希拉諾斯醫療公司 結合erfe之抗體及使用方法
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
MX2021014973A (es) 2019-06-07 2022-04-18 Adimab Llc Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
CN119306824B (zh) * 2024-10-08 2025-09-26 江苏埃尔迪生物科技有限公司 一种全价展示scFv的通用型M13噬菌体探针及其构建方法和应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
DE69738522T2 (de) 1996-08-02 2009-04-02 Bristol-Myers Squibb Co. Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
SI1706424T1 (sl) 2004-01-12 2010-01-29 Applied Molecular Evolution Variante fc regij
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
CN101193654A (zh) 2005-06-14 2008-06-04 赛托斯生物技术公司 抗原偶联物及其用途
US8460364B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
EP2097447A4 (en) * 2006-11-15 2010-12-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE
WO2008151204A1 (en) 2007-06-04 2008-12-11 Sequent Medical Inc. Methods and devices for treatment of vascular defects
ES2529174T3 (es) * 2007-06-12 2015-02-17 Ac Immune S.A. Anticuerpos humanizados para amiloide beta
MX338397B (es) 2007-08-29 2016-04-15 Sanofi Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
CN101888856B (zh) * 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
EP2420245A1 (en) * 2010-08-18 2012-02-22 Max-Delbrück-Centrum Für Molekulare Medizin Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
HUE037720T2 (hu) * 2012-03-28 2018-09-28 Sanofi Sa Bradikinin B1 receptor ligandumok elleni antitestek
US9958572B2 (en) 2015-03-31 2018-05-01 Halliburton Energy Services, Inc. Synthetic test beds for fracturing optimization and methods of manufacture and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biochimia et Biophysica Acta, Vol 842, Pages 90-99(1985)
Regulatory Peptide, Vol.33, pp.321-329(1991.)

Also Published As

Publication number Publication date
JP2021166538A (ja) 2021-10-21
RS57413B1 (sr) 2018-09-28
TW201343671A (zh) 2013-11-01
UY34682A (es) 2013-10-31
US20180222967A1 (en) 2018-08-09
GT201400192A (es) 2015-07-29
TR201808486T4 (tr) 2018-07-23
EP2831113B1 (en) 2018-03-14
JP2019050822A (ja) 2019-04-04
CN104334578B (zh) 2021-10-08
EP3246339A1 (en) 2017-11-22
JP2024038036A (ja) 2024-03-19
PL2831113T3 (pl) 2018-08-31
HUE037720T2 (hu) 2018-09-28
PH12014501970A1 (en) 2014-11-17
DK3246339T3 (da) 2020-01-27
CN113773385B (zh) 2025-09-12
US9879079B2 (en) 2018-01-30
MX361874B (es) 2018-12-18
DOP2014000199A (es) 2014-10-31
ES2673869T3 (es) 2018-06-26
KR102035882B1 (ko) 2019-10-24
MX2014011688A (es) 2015-01-22
MY166157A (en) 2018-06-06
MY184037A (en) 2021-03-17
EP2831113A1 (en) 2015-02-04
SG11201405162YA (en) 2014-09-26
CN113773385A (zh) 2021-12-10
KR20220031728A (ko) 2022-03-11
CL2014002590A1 (es) 2015-01-16
IL234830B (en) 2018-11-29
JP2025134874A (ja) 2025-09-17
KR20200121370A (ko) 2020-10-23
CL2017003039A1 (es) 2018-03-16
CN120441698A (zh) 2025-08-08
MX2018015914A (es) 2021-12-08
WO2013148296A1 (en) 2013-10-03
PT2831113T (pt) 2018-06-20
KR20150002679A (ko) 2015-01-07
CA2868353A1 (en) 2013-10-03
EA201491784A1 (ru) 2015-02-27
HK1206754A1 (en) 2016-01-15
JP6912441B2 (ja) 2021-08-04
NZ631543A (en) 2017-03-31
US20160368976A1 (en) 2016-12-22
SG10201702396QA (en) 2017-04-27
UA117097C2 (uk) 2018-06-25
CO7111293A2 (es) 2014-11-10
CA2868353C (en) 2023-10-31
AU2013240242A1 (en) 2014-10-02
CR20140440A (es) 2014-11-17
US10465002B2 (en) 2019-11-05
US20150050270A1 (en) 2015-02-19
JP2015513903A (ja) 2015-05-18
LT2831113T (lt) 2018-06-25
US20200115441A1 (en) 2020-04-16
AR090352A1 (es) 2014-11-05
BR112014024282A2 (pt) 2017-08-08
MA37407B1 (fr) 2018-03-30
US9376494B2 (en) 2016-06-28
KR102166083B1 (ko) 2020-10-16
EP3246339B1 (en) 2019-10-09
KR20190121861A (ko) 2019-10-28
SI2831113T1 (en) 2018-08-31
TWI605060B (zh) 2017-11-11
AU2018203081A1 (en) 2018-05-24
PE20142170A1 (es) 2015-01-07
DK2831113T3 (en) 2018-06-25
CN104334578A (zh) 2015-02-04
JP6779012B2 (ja) 2020-11-04
JP7411609B2 (ja) 2024-01-11
HRP20180928T1 (hr) 2018-07-27
US12558420B2 (en) 2026-02-24
MA37407A1 (fr) 2016-05-31
CY1121466T1 (el) 2020-05-29
AU2013240242B2 (en) 2018-02-08
US20230399388A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
US12558420B2 (en) Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin
AU2014306649A1 (en) Antibodies to Plasminogen Activator inhibitor-1 (PAI-1) and uses thereof
HK1206754B (en) Antibodies to bradykinin b1 receptor ligands
OA17139A (en) Antibodies to bradykinin B1 receptor ligands

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5